Background {#Sec1}
==========

Anti-glomerular basement membrane (GBM) glomerulonephritis is an autoimmune glomerular disease that is characterized by linear deposition of IgG along the GBM. The main target of anti-GBM antibody had been shown to lie in the NC1 domain of α3 chains of type IV collagen on the GBM. Histologically, it is associated with extensive crescent formation and clinically with rapidly progressive glomerulonephritis (RPGN). There are well-known associations between anti-GBM glomerulonephritis and the presence of antineutrophil cytoplasmic antibody (ANCA) and between anti-GBM glomerulonephritis and membranous nephropathy \[[@CR1]--[@CR3]\]. In a limited number of cases, anti-GBM glomerulonephritis has been associated with IgA nephropathy and other immune complex glomerulonephritis \[[@CR4]--[@CR6]\].

Herein, we report a patient with a diagnosis of anti-GBM disease during the course of IgA nephropathy.

Case presentation {#Sec2}
=================

A 66-year-old woman with a significant past medical history of well-controlled hypertension was admitted with complaints of microscopic hematuria and mild proteinuria for the past 3 years. Serum creatinine level was within normal range at that time and therefore the anti-GBM antibody was not tested. The first renal biopsy revealed mesangial proliferative glomerulonephritis with fibro-cellular crescents in one out of 18 glomeruli, excluding one global sclerotic glomerulus (Fig. [1a](#Fig1){ref-type="fig"}), and deposition of IgA and C3 in mesangial areas by immunofluorescence microscopy (Fig. [2a](#Fig2){ref-type="fig"}). Weak but significant IgG deposition was also observed in glomeruli in the distribution somewhat different from IgA or C3 (Fig. [2a](#Fig2){ref-type="fig"}). The electron-dense deposits were observed in mesangial areas by electron microscopy. Therefore, the diagnosis was IgA nephropathy. Antihypertensive therapy was initiated, mainly with an RAS inhibitor. Eight months later, the patient's serum creatinine suddenly rose to 4.53 mg/dL (it was 1.04 mg/dL from the routine blood test 1 month before). Urinalysis showed 100 red blood cells per high power field and urinary protein excretion of 12.3 g/g~Cr~ (Fig. [3](#Fig3){ref-type="fig"}). The serological tests that were performed to differentiate the cause of rapidly progressive glomerulonephritis revealed the presence of anti-GBM antibody at the titer of 116 IU/mL and the absence of anti-nuclear antibody and anti-neutrophil cytoplasmic antibody. Laboratory findings on admission are summarized in the Table [1](#Tab1){ref-type="table"}.Fig. 1Representative photographs of Periodic acid-Schiff stained sections (Scale bars = 50.0 μm). **a** First renal biopsy showing mesangial proliferative glomerulonephritis with fibro-cellular crescent in one glomerulus. **b** Second renal biopsy showing diffuse crescent formation and a few residual glomerular tufts. Scale bars = 50.0 μmFig. 2Representative photographs of immunofluorescence staining (Scale bars = 20.0 μm). **a** First renal biopsy showing positive staining of IgA, IgG, and C3. The staining pattern was similar in IgA and C3 (granular deposition probably in the mesangial area), but was rather different in IgG. **b** Second renal biopsy showing linear immunofluorescence for IgG along the glomerular capillary walls. IgA staining was found in mesangial areas, whereas C3 deposition was observed in mesangial areas as well as partially in the glomerular capillary wallsFig. 3Clinical course before admission. Cre: serum creatinine levelTable 1Laboratory data on admissionCBC WBC (4000--8000)10,500/μL RBC (390--510)379 × 10^4^/μL Hb (12.0--16.0)11.3 g/dL PLT (15--35)36.9 × 10^4^/μLChemistry TP (6.4--8.0)6.4 g/dL Alb (3.4--5.0)2.8 g/dL AST (8--40)30 U/L ALT (4--43)21 U/L LDH (106--220)345 mg/dL BUN (8--20)35.6 mg/dL Cr (0.5--0.8)5.53 mg/dL Na (135--147)136 mEq/L K (3.4--4.9)3.9 mEq/L Cl (98--108)103 mEq/L Ca (8.0--10.5)7.9 mg/dL P (2.7--4.5)6.1 mg/dL CRP (\< 0.02)1.16 mg/dLImmune-related C3 (86--160)145 mg/dL C4 (17--45)51.3 g/dL CH50 (30--45)76.8 U/mL IgG (380--1620)881 mg/dL IgA (84--438)186 mg/dL IgM (57--288)33 mg/dL ASO (\< 166)22 IU/mL ANA (\< 40)\< 40 Anti --GBM antibody (\< 3.0)116 IU/mL PR3-ANCA (\< 3.5)\<1.0 IU/mL MPO-ANCA (\< 3.5)\<1.0 IU/mLUrinalysis Occult blood3+ RBCs\>100/HPF Protein4 + 12.3 g/gCr WBC1--4/HPF CastGranular cast(+)RBCcast(+)*WBC* white blood cells, *RBC* red blood cells, *Hb* hemoglobin, *Plt* platelets, *HPF* high-power field, *TP* total protein, *Alb* albumin, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *LDH* lactate dehydrogenase, *BUN* blood urea nitrogen, *Cr* creatinine, *Na* sodium, *K* potassium, *Cl* chloride, *Ca* calcium, *P* phosphate, *CRP* C-reactive protein, *ANA* anti-nuclear antibody, *GBM* glomerular basement membrane, *ANCA* anti-neutrophil cytoplasmic antibody, *PR3* proteinase 3, *MPO* myeloperoxidase

After admission, treatments with hemodialysis, plasma exchange, and intravenous methylprednisolone pulse therapy followed by oral prednisolone at the dose of 50 mg/day were initiated. The second renal biopsy was performed at 4 weeks after admission in order to assess the probability of renal recovery and to make the final diagnosis. It revealed cellular to fibrocellular crescents in 18 of 25 glomeruli, excluding six global sclerotic glomeruli by light microscopy. By immunofluorescence study, linear IgG deposition along the glomerular capillary walls and mesangial staining for IgA were observed. On the other hand, C3 deposition was observed in the mesangium as well as in the glomerular capillary walls (Fig. [2b](#Fig2){ref-type="fig"}). Electron-dense deposits were observed in mesangial areas, similarly as in the first biopsy, by electron microscopy (Fig. [4](#Fig4){ref-type="fig"}). Based on the aforementioned findings, the diagnosis of anti-GBM glomerulonephritis and IgA nephropathy was confirmed. Plasmapheresis was performed eight times, anti-GBM antibody gradually decreased, and alveolar hemorrhage was prevented. However, her renal function could not be restored and she underwent maintenance hemodialysis (Fig. [5](#Fig5){ref-type="fig"}).Fig. 4Electron microscopic photograph of the second renal biopsy, showing the electron-dense deposits in mesangial areasFig. 5Clinical course after admission. Cre: serum creatinine level, Anti-GBM antibody: anti-glomerular basement membrane antibody, PEX: plasma exchange, mPSL: methylprednisolone, PSL: prednisolone, HD: hemodialysis, RBX: renal biopsy

Additional immunosuppressant was not given because the patient did not show any sign of pulmonary involvement and because the renal recovery was quite unlikely from clinical (continuous oliguria and hemodialysis dependence) as well as histological (crescent formation in most of non-sclerotic glomeruli) point of view.

Clinical and histological presentations from IgA nephropathy (at the time of first renal biopsy) and from anti-GBM disease (at the time of second renal biopsy) were summarized in the Table [2](#Tab2){ref-type="table"}.Table 2Clinical and histological presentation at the time of first and second renal biopsyFirst biopsySecond biopsyClinical presentationCGNRPGNU-P 3.2 g/g·CrU-P 12.3 g/g·CrU-RBC 50--99/HPFU-RBC \> 100/HPFsCr 0.74 mg/dLsCr 5.5 mg/dLAnti-GBM antibodyNot tested116 IU/mlLight microscopyMesangial proliferative GNCrescentic GNGlobal sclerosis (1/19)Global sclerosis (6/31)Fibrocellular crescent (1/19)Cellular\~fibrocellular crecent (18/31)ImmunofluorescenceIgA: mes ++IgA: mes +C3: mes ++C3: mes +IgG: mes +, peripheral linear + peripheral linear ±IgG: peripheral linear ++ (focal segmental) (diffuse global)*CGN* chronic glomerulonephritis, *RPGN* rapidly progressive glomerulonephritis, *GBM* glomerular basement membrane, *GN* glomerulonephritis, *mes* mesangium

Discussion and conclusions {#Sec3}
==========================

IgA nephropathy is an immune complex-mediated glomerulonephritis defined immunohistologically by the presence of glomerular mesangial IgA deposits accompanied by a variety of histopathologic lesions, including mesangial proliferation \[[@CR7]\]. Anti-GBM disease is caused by antibodies reactive to the glomerular and alveolar basement membrane.

The causal relationship of anti-GBM glomerulonephritis and IgA nephropathy is unclear. There was one hypothesis that the IgA-related immune complex might promote immunologic and inflammatory events, resulting in conformational changes and exposure of the GBM antigens leading to development of anti-GBM antibody \[[@CR4]\]. However, it is difficult to prove whether anti-GBM disease in this patient developed as an incidental complication or was secondary to IgA nephropathy because there is still no established marker to distinguish primary from secondary anti-GBM disease. In this regard, we performed immunofluorescence staining for IgG subclasses on the second renal biopsy, and found that IgG4 was the main subclass of IgG bound to GBM in this patient (Fig. [6](#Fig6){ref-type="fig"}). The main subclass of pathogenic IgG in anti-GBM disease was reported to be usually IgG1 \[[@CR8]\]. Whether predominance of IgG4 relates with anti-GBM disease developed secondary to IgA nephropathy deserves future study.Fig. 6Immunofluorescence staining for IgG subclasses on the second renal biopsy (Scale bars = 20.0 μm). The main subclass of IgG bound to GBM was IgG4

The pathophysiological condition of anti-GBM disease before clinical presentation is unknown. In this regard, Olson et al. conducted a case-control study involving 30 patients diagnosed with anti-GBM disease using serum samples from the Department of Defense Serum Repository. In the report, 13% (4 of 30) of study subjects had an elevated anti-GBM antibody level 2--10 months prior to diagnosis \[[@CR9]\]. In the present case, multiple immunofluorescence labelling on the first biopsy showed partial linear IgG deposition along the glomerular capillary walls (Fig. [7](#Fig7){ref-type="fig"}). Although it may be only speculation because serum anti-GBM antibody was not tested at the time of the first biopsy, the patient might have had complications from asymptomatic (subclinical) anti-GBM disease at that point.Fig. 7Multiple immunofluorescence staining for IgG (FITC: green), C3 (Alexa Fluor 594: red) and DAPI (blue) on the first biopsy. A linear IgG-positive portion was observed partially along the glomerular capillary walls as indicated by white arrows. Scale bar = 10.0 μm

In the case of IgA nephropathy complicated by anti-GBM disease, Yamaguchi et al. speculated that the pathological features of IgA nephropathy may not be observed because the number of glomeruli free from destruction is very limited \[[@CR10]\]. Therefore, the coexistence of anti-GBM glomerulonephritis and IgA nephropathy may be more frequent than is being reported.

In summary, we reported a patient with a diagnosis of anti-GBM disease during the course of IgA nephropathy. Histological evaluation could be performed before and after the development of anti-GBM disease over a period of 10 months. Even if the patient had already received a diagnosis of a chronic glomerulonephritis such as IgA nephropathy, we should check autoantibodies to rule out overlapping autoimmune conditions in case the patient showed an unusually rapid clinical course.
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